BioCentury
ARTICLE | Product Development

Tregs and gene regulation define Sangamo’s next act

Sangamo takes a second shot at a first mover advantage as it pivots from gene editing to engineering Treg cell therapies

February 9, 2022 11:47 AM UTC

More than 25 years into its story, pioneering gene editing company Sangamo is shifting gears to focus on a leadership opportunity in the emerging regulatory T cell therapy space, but the company is not abandoning its zinc finger protein roots. 

The latest pivot by Sangamo Therapeutics Inc. (NASDAQ:SGMO) reflects the challenge of keeping pace when disruptive technologies threaten to displace a platform, and may prove an example of how to adapt by retooling and redirecting the technology to aim for a lead position in a less competitive space...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article